Core Viewpoint - Astria Therapeutics, Inc. has announced the pricing of an underwritten offering of 10,340,000 shares of its common stock at a price of 125 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering is expected to close on or about February 1, 2024, pending customary closing conditions [1]. - The financing was led by RA Capital Management, with participation from several notable investors including Perceptive Advisors and Venrock Healthcare Capital Partners [2]. - Jefferies and Evercore ISI are acting as joint book-running managers for the offering, with LifeSci Capital serving as the lead manager [2]. Group 2: Company Overview - Astria Therapeutics is focused on developing therapies for allergic and immunological diseases, with its lead program STAR-0215 being a monoclonal antibody inhibitor of plasma kallikrein for hereditary angioedema [5]. - The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist for atopic dermatitis, which is currently in preclinical development [5]. Group 3: Regulatory Information - The securities are being offered under a shelf registration statement on Form S-3, which was declared effective by the SEC on December 29, 2023 [3]. - A final prospectus supplement will be filed with the SEC and will be available for public access [3].
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering